Objective: In systemic sclerosis (SSc), pulmonary function tests (PFTs) have been included in screening algorithms for pulmonary hypertension (PH). However, in combined pulmonary fibrosis and emphysema (CPFE), the interpretation of PFT is confounded. We examined the prevalence of CPFE in SSc patients with interstitial lung disease (SSc-ILD) and the effect of CPFE on PFTs used to evaluate the severity of SSc-ILD and the likelihood of PH.
INTRODUCTION
In systemic sclerosis (SSc), pulmonary involvement (including interstitial lung disease and pulmonary hypertension [PH] ) is the most common cause of death (1).
Interstitial lung disease in SSc [SSc-ILD] ranges from sub-clinical lung involvement to major pulmonary disease progressing to respiratory failure and death (2). The severity of SSc-ILD is most frequently quantified in routine practice using pulmonary function tests. Carbon monoxide diffusing capacity (DLco) levels best reflect the morphologic extent of SSc-ILD on high resolution computed tomography (HRCT) (3) but are also profoundly affected by presence of PH. More recently, an increased FVC/DLco ratio has been advocated as a determinant of which SSc patients should undergo echocardiographic screening for PH ( 4-7).
There is reason to suspect that concurrent emphysema may seriously confound pulmonary function tests in SSc-ILD. In idiopathic pulmonary fibrosis (IPF), concurrent emphysema has been associated with spurious preservation of forced vital capacity (FVC) levels, devastating reductions in DLco levels (8) and, by implication, major effects on FVC/DLco ratios. Parallel analyses have yet to be performed in suitably large cohorts of SSc-ILD patients, despite the fact that the combination of pulmonary fibrosis and emphysema (CPFE) occurs in SSc (9) . Therefore, the aims of our study were a) to examine the prevalence of emphysema in a large SSc-ILD cohort and b) to determine whether the presence of emphysema has a major confounding effect on pulmonary function tests used to evaluate interstitial lung disease severity and the likelihood of PH in SSc-ILD.
PATIENTS and METHODS

Methods
The study population consisted of 333 patients with SSc-ILD, referred between Tables 1 and 2: analyses of serological status were confined to patients undergoing testing at presentation in the same laboratory (n=308).
Clinical data
"Ever smokers" had smoked at least one cigarette per day for at least one year. Packyear smoking histories were recorded. In three cases, the smoking history was considered to be unreliable: these patients were excluded from the analyses.
Pulmonary function tests, echocardiography and HRCT were performed as previously reported (11) (12) .
Echocardiographic evaluation included estimation of pulmonary arterial systolic pressure from tricuspid regurgitant jet velocity, the identification of right ventricular or right atrial enlargement, and the evaluation of right ventricular function.
Echocardiographic pulmonary hypertension was defined as a pulmonary arterial systolic pressure of 40 mm Hg or greater. Echocardiography was routinely performed at presentation: 25 of 333 patients not undergoing echocardiography at our institution were excluded from echocardiographic analyses.
HRCT sections (1.5mm -3mm) were acquired supine, at full inspiration, at 10mm intervals (window center = -550 Hounsfield units (HU); window width = 1500 HU), using an electron beam scanner (Imatron Inc., San Francisco, CA). Scans were scored independently by two observers (AUW and SRD), blinded to clinical and lung function information. HRCT features were scored as five levels, defined using anatomical landmarks, as described previously (13) (14) , as follows:
-The extent of interstitial lung disease was estimated to the nearest five percent in each section, with global extent of disease on HRCT computed as the mean of the scores for section. Discrepancies of more than 20% in global scores were resolved by consensus.
-The extent of emphysema was estimated to the nearest five percent in each section, with global extent of disease on HRCT computed as the mean of the scores for section. Disagreement on the presence or absence of emphysema and discrepancies of more than 20% in global scores were resolved by consensus. To be scored as present, emphysema was required to be separate geographically from interstitial fibrosis. Two patients, in whom there was limited emphysematoid destruction within fibrotic lung, with no additional emphysema in other lung regions, were scored as not having emphysema.
-The distributions of interstitial lung disease and emphysema were 
Data analysis
Analyses were performed using STATA software (Stata data analysis software;
Computing Resource Centre, Santa Monica, CA). Data were expressed as means (SD) or medians (range), depending on distribution. Group comparisons were made using Student's t test, Wilcoxon rank sum, chi-squared statistics and Fisher's exact test, as appropriate. A p-value of <0.05 was considered significant. Inter-observer variation was quantified as the kappa coefficient of agreement for the presence of emphysema and the single-determination standard deviation for a) the extent of interstitial lung disease; and b) the extent of emphysema.
Correlations between the extent of interstitial lung disease and individual PFTs were examined using Pearson's product moment correlation. Univariate and multivariate analyses were performed. Logistic regression was used to identify independent associations with a) the presence of emphysema; and b) FVC/DLco threshold values of >1.6 and >2.0. Multiple linear regression models were constructed to identify the independent determinants of levels of individual PFT. Models were formally tested for heteroscedasticity to confirm that the assumptions of parametric analysis had been satisfied.
RESULTS
Inter-observer variation for HRCT observations
Agreement was good for the presence of emphysema (kappa coefficient of agreement = 0.64). The single determination standard deviation for the extent of interstitial lung disease was 4.1%. 
Sub
The effect of emphysema and smoking status on pulmonary function variables
The extent of interstitial lung disease on HRCT was negatively related to % predicted Table 3 , the extent of interstitial lung disease and the presence of emphysema were independent determinants of % predicted DLco levels.
As shown in
Smoking status provided no independent linkage to DLco levels whether quantified as "ever/never smoking" or as the pack-year smoking history. These In 311 patients undergoing concurrent echocardiography, the extent of interstitial lung disease, the presence of emphysema and the presence of pulmonary hypertension were independent negative determinants of % predicted DLco levels.
The independent effects of the extent of interstitial lung disease, the presence of emphysema and smoking status (current/former smokers versus lifelong non-smokers) upon other pulmonary function variables are shown in Table 2 (with adjustment for age and gender). Indices of gas exchange (pO2 levels, the alveolar-arterial oxygen gradient) were more strongly influenced by the presence of emphysema than by the smoking status. By contrast, the presence of emphysema had no independent effect on FEV1 or FVC levels (Figure 2) , whereas current or former smokers exhibited relative preservation of spirometric volumes. 
DISCUSSION
The combination of emphysema and fibrosis, also known as the CPFE syndrome, has been reported in patients with CTD-ILD (9). However, the clinical significance of this proposed syndrome has yet to be established. We report a prevalence of emphysema of 12% in a large cohort of SSc-ILD patients, with emphysema present more often in current or former smokers but also ssen in 7.5% of life-long nonsmokers. The presence of emphysema had a significant confounding effect on measures of gas transfer and gas exchange in both smokers and non-smokers. The FVC/DLco ratio, recently advocated as an important screening tool for pulmonary hypertension, was strikingly influenced by the presence of emphysema.
The current study of the prevalence and functional impact of emphysema in a population of over 300 SSc-ILD patients extends and refines the observations of Cottin et al in a series of 34 CTD-ILD patients with CPFE, including 10 with SSc-ILD (9). In small cohorts, emphysema had been observed in a handful of nonsmoking patients with rheumatoid lung (14) and SSc-ILD (9) . The size of the current cohort allows the confident conclusion to be drawn that emphysema has a significant prevalence (7.5%, 95% confidence intervals 4-12%) in non-smokers with SSc-ILD.
Furthermore, the presence of emphysema in smokers with SSc-ILD was associated with a low pack-year smoking history, as also reported in rheumatoid lung (when compared with a control cohort of smokers without interstitial lung disease) (14) .
The size of the current cohort allows the confident conclusion to be drawn that emphysema has a significant prevalence (7.5%, 95% confidence intervals 4-12%) in non-smokers with SSc-ILD. Furthermore, in smokers with SSc-ILD with an average smoking history of only 15 pack-years, emphysema was present in 15%.
Taken together, these observations raise the possibility that SSc-ILD may be a risk factor for the development of emphysema in both smokers and nonsmokers. However, without a control group of smokers without interstitial lung disease, our findings are inconclusive in this regard.
Given the high prevalence of emphysema in non-smokers, it was important to consider the possible confounding effect of inter-observer variability with regard to the presence of trivial emphysema. However, the extent of emphysema did not differ between smokers and non-smokers. More importantly, the presence of emphysema in non-smokers had the same effect on measures of gas transfer and gas exchange as in smokers. For a given extent of fibrosis, the presence of emphysema was associated with a reduction in DLco of over 10% in both smokers and non-smokers. Strikingly, the FVC/DLco ratio rose, on average, by over 40% from the observed values in both smokers and non-smokers with emphysema, after adjustment for other variables.
Given the major functional effects associated with emphysema in non-smokers, despite the relatively limited extent of emphysema, it appears difficult to argue that our findings have been materially affected by methodological limitations or interobserver variability.
The reported pattern of functional impairment in patients with combined emphysema and fibrosis has consisted of relative preservation of lung volumes and a disproportionate reduction in DLco levels (8) (9) (15) (16) (17) . In most reports, the relative impact of concurrent emphysema on lung volumes and measures of gas transfer has not been quantified definitively (i.e. with the extent of fibrosis also taken into account in multivariate analysis). However, in the current study, as in an early IPF study (18) , the presence of emphysema had a much greater effect on DLco levels than FVC levels (which were not significantly affected). These findings suggest that the presence of emphysema is unlikely to confound the accurate use of FVC in prognostic evaluation, as in an SSc-ILD staging system (19) recently validated against survival (20) . By contrast, the lack of relative preservation in FVC levels in patients with emphysema is likely to reflect the fact that spirometric volumes are influenced by smoking-related intrinsic airway inflammation, in a larger smoking patient subgroup, irrespective of the presence or absence of emphysema.
Our observations indicate that the presence of emphysema has a major confounding effect on the contribution of pulmonary function tests to non-invasive screening for PH in SSc-ILD. Functional abnormalities typically seen in PH include undue hypoxia (21) and reductions in DLco that are disproportionate to lung volumes, quantified historically by adjustment of DLco for alveolar volume (DLco/VA, Kco) and more recently by the FVC/DLco ratio (22) . In SSc, an increased FVC/DLco ratio, alone or in combination with other variables, has provided justification for the performance of a right heart study, based on thresholds of 1.6 (4-5,7) or 2.0 (6).
However, in routine practice, pulmonary physiologic profiles suggestive of PH generally lead to the performance of echocardiography rather than immediate right heart catheterisation, a sequence reproduced in the recent prospective two-step DETECT algorithm (23) . In that study, the FVC/DLco ratio was validated against echocardiographic data and was found to be one of the two non-invasive variables most strongly predictive of echocardiographic PH. However, the DETECT algorithm was developed in SSc in general and has not been tested specifically in SSc-ILD. Therefore, we report the first evaluation of the accuracy of the FVC/DLco ratio against echocardiographic data in SSc-ILD, with particular reference to the presence or absence of concurrent emphysema. Echocardiographic criteria for PH in the current study were essentially those validated in the DETECT study against the presence of PH at right heart catheterisation. Taken together, the prevalence of emphysema in SSc-ILD in the current study, the major confounding effect of emphysema on physiologic variables and the importance of the FVC/DLco ratio in the DETECT algorithm have prompted us to conclude that the DETECT algorithm may need to be adapted in patients with SSc-ILD. One important proviso is that this needs to be done in smokers and non-smokers alike. Based on our findings, it appears that major increases in the FVC/DLco ratio are not indicative of a high likelihood of PH on echocardiography, when emphysema is present on HRCT.
Given the aims of the current study, our findings have only indirect implications with regard to pathogenetic linkages between emphysema and interstitial lung disease in SSc. However, the predilection for the development of emphysema in smoking and non-smoking patients with SSc-ILD was striking, taking into account the low packyear history associated with emphysema in smokers. A number of candidate pathways are common to emphysema and interstitial lung disease, including oxidative stress (24) (25) , matrix remodeling (26) (27) , protein citrullination (28) (29) (30) , elastin activation (31-32) and telomerase regulation (33) . There is also the intriguing possibility that autoimmune pathways might be implicated both in CTD-ILD and in the pathogenesis of emphysema, accounting for the existence of emphysema in some non-smokers with SSc-ILD. Evidence of immune dysregulation has emerged in chronic obstructive pulmonary disease cohorts (34) (35) , including dysfunction of T regulatory cells and dendritic cells (36) , autoantibody expression (32) and systemic manifestations compatible with autoimmunity (37).
One limitation of the current study is the fact that patients underwent right heart catheterisation only if the echocardiographic findings were suggestive of PH. The acquisition of right heart data in all cases would have allowed FVC/DLco thresholds to be evaluated for sensitivity, specificity and predictive values against proven PH.
However, it is doubtful that such a protocol in a large cohort of SSc-ILD patients is achievable. It can also be argued that examination against echocardiography is a relevant evaluation of the true clinical utility of the FVC/DLco ratio, which may lie We stress that we cannot exclude the possibility that the relatively high prevalence of emphysema in non-smokers in SSc-ILD might apply equally to SSc patients without interstitial lung disease. The nature of our cohort, which consisted of consecutive SSc patients with known or suspected lung involvement, did not allow this possibility to be explored. Given the referral pattern to our institution, it was considered highly unlikely that the relatively small subset of patients without interstitial lung disease were representative of the larger non-referred SSc population. We suggest that further evaluations based on our findings might usefully be undertaken in SSc cohorts not selected for the presence of lung involvement. However, a powerful argument against a major excess of emphysema in the absence of interstitial lung disease is the finding that the FVC/DLco ratio was, in fact, strongly linked to echocardiographic evidence of PH in the whole SSc cohort evaluated in the DETECT study.
In conclusion, we report a predilection to emphysema in SSc-ILD, as shown by its sporadic presence in non-smokers and a low associated pack-year smoking history in smokers. The significance prevalence of emphysema in non-smokers with SSc-ILD provides indirect support for a pathogenetic basis for a syndrome of CPFE. The CPFE syndrome is associated with disproportionate impairment of measures of gas transfer and gas exchange, including a major confounding effect on the FVC/DLco ratio. These findings have major implications for the construction of accurate screening algorithms for PH in SSc-ILD. approximately 35% of baseline levels), after adjustment for the extent of interstitial lung disease, age and the presence of pulmonary hypertension, as judged by echocardiography.
